Trisalus Life Sciences (TLSI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
31 Mar, 2026Voting matters and shareholder proposals
Election of two director nominees, Mary Szela and Gary Gordon, to serve until the 2029 Annual Meeting or until earlier departure.
Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on the frequency of future stockholder advisory votes on executive compensation, with a recommendation for every three years.
Advisory vote on the compensation of named executive officers.
Provision for other business to be addressed as may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Two nominees, Mary Szela and Gary Gordon, are recommended for election to the board.
Audit committee and external auditor matters
Grant Thornton LLP is recommended for ratification as the independent registered public accounting firm for the upcoming fiscal year.
Latest events from Trisalus Life Sciences
- Innovative catheter tech, new FDA-cleared products, and expanded reimbursement fuel rapid growth.TLSI
Canaccord Genuity's 46th Annual Growth Conference - Q2 revenue reached $11.4M, gross margin hit 88%, and 2026 guidance was reaffirmed.TLSI
Q2 2026 - PEDD platform and TriNav system target $2.5B+ market with strong growth and clinical momentum.TLSI
Investor presentation - Q1 2026 saw revenue dip but net income turned positive amid expansion and strong PEDD data.TLSI
Q1 2026 - Proxy covers director elections, auditor ratification, and executive compensation votes.TLSI
Proxy filing - Strong revenue growth, expanded product suite, and robust 2026 outlook with $46M new capital.TLSI
Q4 2025 - Q3 revenue up 42% YoY; 2025 outlook targets 50%+ sales growth and positive EBITDA, but funding risk remains.TLSI
Q3 2024 - Rapid growth in drug delivery tech, new clinical data, and EBITDA positive targeted for 2025.TLSI
Maxim Group’s 2024 Healthcare Virtual Summit - Q2 revenue up 60% to $7.4M, gross margin at 88%, and net loss narrowed to $4.3M.TLSI
Q2 2024